Research Details

Human Chorionic Gonadotropin — HCG Scientific Research Overview Human chorionic gonadotropin is a glycoprotein hormone with biological activity similar to luteinizing hormone. HCG interacts with luteinizing-hormone/chorionic-gonadotropin receptors and has been studied extensively in reproductive endocrinology, including Leydig-cell signaling, testosterone production, testicular development, spermatogenesis, final follicular maturation, and ovulation. Published Research Findings In a long-term study involving 17 males with isolated hypogonadotropic hypogonadism, HCG treatment increased testosterone and testicular volume. Thirteen participants, approximately 70%, became sperm-positive during HCG-only treatment. The study supported HCG’s ability to stimulate spermatogenic activity in appropriately selected participants, although responses varied according to individual endocrine characteristics. Other clinical research has found that HCG can stimulate testicular growth and testosterone production, while some participants with more complete gonadotropin deficiency require additional follicle-stimulating hormone activity to achieve stronger spermatogenic responses. In assisted-reproduction research, HCG has been studied as a trigger for final follicular maturation and ovulation. Comparative studies generally found that recombinant and urinary HCG preparations produced similar overall clinical outcomes, although individual studies reported differences in selected laboratory or oocyte-development measurements. Evidence and Regulatory Context Specific HCG prescription products have FDA-approved indications involving selected cases of male hypogonadotropic hypogonadism, certain cases of prepubertal cryptorchidism, and induction of ovulation and pregnancy in appropriately selected patients. These approvals apply only to the FDA-reviewed finished drug products. Research Links Long-Term HCG Therapy and Spermatogenesis in Isolated Hypogonadotropic Hypogonadism Gonadotropin Therapy and Factors Affecting the Response to HCG Recombinant Versus Urinary HCG for Triggering Ovulation FDA Pregnyl Prescribing Information Research Context: Published findings summarized on this page involve controlled studies of the named hormone and, where applicable, regulated pharmaceutical formulations. These findings do not establish the identity, purity, sterility, safety, effectiveness, or regulatory status of the research material offered on this page. This product is sold strictly for lawful laboratory research and is not intended for human or veterinary use.